Each year, the U.S. Drug Enforcement Administration pools the knowledge of law enforcement agencies around the country to produce its National Drug Threat Assessment. This year, fentanyl, counterfeit prescription pills, and the pill presses are all listed as things that will continue to endanger American lives…
Read More
Yesterday ended a 78-day comment period for the White House’s proposal to import medicine from Canada. In all, over 1,000 comments were filed. Overwhelmingly, these comments opposed the proposed rule or expressed skepticism that the rule could meet the two requirements listed in the Medicare Modernization Act of 2003: be safe and save consumers money. In fact, when you read the comments, it is clear that this policy is overwhelming opposed by experts on the issues of economics and medicine safety.
Read More
According to a notice on the L.A. City Attorney’s website, the Dominguez family allegedly ran a counterfeit drug operation that sold approximately 13,848 counterfeit and misbranded pharmaceuticals, including counterfeit and misbranded versions of anti-seizure and blood pressure medications, injectable birth control and steroids, among others.
Read More
This editorial by Peter J. Pitts was published in The Times Weekly on March 3, 2020. Mr. Pitts is president of the Center for Medicine in the Public Interest and a former FDA associate commissioner. Keep Canadian drugs out of U.S. medicine cabinets The Trump administration recently proposed two rules that would allow states, pharmacies,…
Read More
WHOIS data is searchable registrar information available for all websites on the Internet. It has long been used to trace criminal websites that host counterfeit and illicit drug sales, human trafficking, child pornography, and illicit and copyrighted content, as well as the websites of spammers, denial-of-services and phishing attackers, and other fraudsters.
Read More
In this editorial in The Globe and Mail, Ujjal Dosanjh, formerly a federal minister of health and a premier of British Columbia, explains that drug manufacturers have no incentive to sell Canadian provinces more medicine to fill the needs of U.S. residents. Importation will lead to drug shortages in Canada and counterfeit drug trafficking to the U.S.
Read MoreThis is a reprint of an FDA Alert. When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company’s announcement as a public service. FDA does not endorse either the product or the company. Company Announcement Date: February 24, 2020 FDA Publish Date: February 24, 2020 Product Type: Dietary Supplements…
Read More
The U.S. Food and Drug Administration (FDA) has just announced a successful joint operation with the Government of India targeting counterfeit prescription drugs, counterfeit over-the-counter medications, fake medical devices, and misbranded dietary supplements containing harmful ingredients.
Read More
Today The Partnership for Safe Medicines filed comments with Health and Human Services about the dangers posed by its draft regulations for state-based Canadian drug importation programs. PSM cited historic problems with and patient harm from Canadian vendors selling counterfeit medications to U.S. patients and medical practices; showed broad opposition to the plan by Canadian stakeholders; and provides alternatives that don’t impact patient safety.
Read More
According to a report from Europol’s Intellectual Property Crime Threat Assessment 2019, “Counterfeit pharmaceuticals pose a growing threat to the EU, affecting a large number of Member States. A wide and increasingly diverse range of medicines is targeted by counterfeiters.”
The Europol ICP Threat Assessment reports that there has been an increase in seizures of counterfeit drugs used in the treatment of serious illnesses, as well as a growing number of counterfeit drug incidents affecting the legal drug supply chain.